Employment disruption following the diagnosis of endometrial cancer
- PMID: 33183765
- PMCID: PMC7779695
- DOI: 10.1016/j.ygyno.2020.10.041
Employment disruption following the diagnosis of endometrial cancer
Abstract
Background: Oncologic treatment has been associated with unemployment. As endometrial cancer is highly curable, it is important to assess whether patients experience employment disruption after treatment. We evaluated the frequency of employment change following endometrial cancer diagnosis and assessed factors associated with it.
Methods: A cohort of patients 18-63 years-old who were diagnosed with endometrial cancer (January 2009-December 2017) were identified in the Truven MarketScan database, an insurance claims database of commercially insured patients in the United States. All patients who were working full- or part-time at diagnosis were included and all employment changes during the year following diagnosis were identified. Clinical information, including use of chemotherapy and radiation, were identified using Common Procedural Terminology codes, and International Statistical Classification of Diseases codes. Cox proportional hazards models incorporating measured covariates were used to evaluate the impact of treatment and demographic variables on change in employment status.
Results: A total of 4381 women diagnosed with endometrial cancer who held a full-time or part-time job 12 months prior to diagnosis were identified. Median age at diagnosis was 55 and a minority of patients received adjuvant therapy; 7.9% received chemotherapy, 4.9% received external-beam radiation therapy, and 4.1% received chemoradiation. While most women continued to work following diagnosis, 21.7% (950) experienced a change in employment status. The majority (97.7%) of patients had a full-time job prior to diagnosis. In a multivariable analysis controlling for age, region of residence, comorbidities, insurance plan type and presence of adverse events, chemoradiation recipients were 34% more likely to experience an employment change (HR 1.34, 95% CI 1.01-1.78), compared to those who only underwent surgery.
Conclusion: Approximately 22% of women with employer-subsidized health insurance experienced a change in employment status following the diagnosis of endometrial cancer, an often-curable disease. Chemoradiation was an independent predictor of change in employment.
Keywords: Employment; Endometrial cancer; Survivorship.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Drs. Nitecki, Fu, Melamed, Lefkowits, Giordano and Rauh-Hain have nothing to disclose. Dr. Smith reports grants from Varian Medical Systems, other from Oncora Medical, outside the submitted work. Dr. Meyer reports grants from National Cancer Institute, during the conduct of the study; other from AstraZeneca, outside the submitted work.
Figures
Similar articles
-
Employment disruption among women with gynecologic cancers.Int J Gynecol Cancer. 2022 Jan;32(1):69-78. doi: 10.1136/ijgc-2021-002949. Epub 2021 Nov 16. Int J Gynecol Cancer. 2022. PMID: 34785522 Free PMC article.
-
National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.Am J Obstet Gynecol. 2019 Nov;221(5):474.e1-474.e11. doi: 10.1016/j.ajog.2019.05.029. Epub 2019 May 22. Am J Obstet Gynecol. 2019. PMID: 31128110 Free PMC article.
-
Insurance Coverage, Employment Status, and Financial Well-Being of Young Women Diagnosed with Breast Cancer.Cancer Epidemiol Biomarkers Prev. 2020 Mar;29(3):616-624. doi: 10.1158/1055-9965.EPI-19-0352. Cancer Epidemiol Biomarkers Prev. 2020. PMID: 32132129 Free PMC article.
-
Changes in work status after cancer diagnosis and their associations with depressive symptoms among cancer survivors: findings from the Korean longitudinal study of ageing1.BMC Psychol. 2024 Oct 14;12(1):551. doi: 10.1186/s40359-024-01970-9. BMC Psychol. 2024. PMID: 39402645 Free PMC article.
-
Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.Am J Obstet Gynecol. 2016 Dec;215(6):766.e1-766.e9. doi: 10.1016/j.ajog.2016.07.035. Epub 2016 Jul 22. Am J Obstet Gynecol. 2016. PMID: 27457116 Free PMC article.
Cited by
-
Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States.J Health Econ Outcomes Res. 2023 Nov 8;10(2):104-110. doi: 10.36469/001c.88419. eCollection 2023. J Health Econ Outcomes Res. 2023. PMID: 37954059 Free PMC article.
-
Employment disruption among women with gynecologic cancers.Int J Gynecol Cancer. 2022 Jan;32(1):69-78. doi: 10.1136/ijgc-2021-002949. Epub 2021 Nov 16. Int J Gynecol Cancer. 2022. PMID: 34785522 Free PMC article.
-
Catastrophic health expenditures, insurance churn, and nonemployment among gynecologic cancer patients in the United States.Am J Obstet Gynecol. 2022 Mar;226(3):384.e1-384.e13. doi: 10.1016/j.ajog.2021.09.034. Epub 2021 Sep 29. Am J Obstet Gynecol. 2022. PMID: 34597606 Free PMC article.
-
Employment Disruption and Financial Burden Associated with Gastrointestinal Cancers.Ann Surg Oncol. 2025 Jun 26. doi: 10.1245/s10434-025-17683-1. Online ahead of print. Ann Surg Oncol. 2025. PMID: 40569357
-
The Impact of BCL11A Polymorphisms on Endometrial Cancer Risk Among Chinese Han Females.Pharmgenomics Pers Med. 2022 Apr 7;15:311-325. doi: 10.2147/PGPM.S345772. eCollection 2022. Pharmgenomics Pers Med. 2022. PMID: 35418772 Free PMC article.
References
-
- American Cancer Society. Facts & Figures 2020. American Cancer Society; Atlanta, Ga: 2020, (n.d.). https://www.cancer.org/cancer/endometrial-cancer/about/key-statistics.html (accessed June 14, 2020).
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials